Literature DB >> 27090907

Parp1 Deficiency Confers Defects in Chromatin Surveillance and Remodeling During Reprogramming by Nuclear Transfer.

Tomoharu Osada1, Tadashige Nozaki, Mitsuko Masutani.   

Abstract

Accumulating evidence suggests that cloned mice production by the injection of a somatic cell nucleus into an enucleated oocyte is inefficient. DNA damage and chromatin remodeling failures that occur during embryogenesis following nuclear transfer (NT) might explain the poor development of cloned embryos. To avoid these problems, it is important to elucidate somatic chromatin remodeling after NT. Because polyADP-ribosylation, which is catalyzed mainly by poly(ADP-ribose) polymerase 1 (Parp1), is a major post-translational modification that facilitates DNA repair and chromatin remodeling, we examined the effects of Parp1 deficiency in developing NT embryos. Parp1 was located within the pseudo-pronuclei (PPN) of NT eggs. We observed that NT eggs, after activation by Sr2+, formed PPN with significantly more efficiency in Parp1-null embryos than in wild-type NT embryos. However, most the Parp1-null embryos stopped developing by the four-cell stage. Immunostaining for γH2AX foci, a marker of DNA double strand breaks, showed longer retention in the PPN of Parp1-/- donor NT embryos than in wild-type NT embryos, suggesting that, in the absence of Parp1, DNA breaks are slowly repaired and consequently, entry into the S phase might be delayed. Furthermore, decreases in histone H3 acetylation, H3 monomethylation at lysine 4, and H3 trimethylation at lysine 27 after the Sr2+ activation step were observed in the PPN of Parp1-/- donor embryos. Taken together, our data suggest that Parp1 is involved in the plastic remodeling of chromatin structure after NT by supporting DNA repair and specific histone code modifications.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27090907     DOI: 10.2174/1389203717666160419144502

Source DB:  PubMed          Journal:  Curr Protein Pept Sci        ISSN: 1389-2037            Impact factor:   3.272


  2 in total

1.  Enhanced Cytotoxicity on Cancer Cells by Combinational Treatment of PARP Inhibitor and 5-Azadeoxycytidine Accompanying Distinct Transcriptional Profiles.

Authors:  Tomonori Araki; Kensuke Hamada; Aung Bhone Myat; Hideki Ogino; Kohei Hayashi; Miho Maeda; Ying Tong; Yasufumi Murakami; Kazuhiko Nakao; Mitsuko Masutani
Journal:  Cancers (Basel)       Date:  2022-08-28       Impact factor: 6.575

2.  RNAi-mediated knockdown of Parp1 does not improve the development of female cloned mouse embryos.

Authors:  Guang-Yu Bai; Si-Hang Song; Rui-Zhen Sun; Zi-Hui Zhang; Jingyu Li; Zhen-Dong Wang; Zhong-Hua Liu; Lei Lei
Journal:  Oncotarget       Date:  2017-07-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.